511 results about "Quinazolinone" patented technology

Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.

The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.

This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.

The invention discloses a quinazolinone compound containing 1, 2, 4-triazole thioether and synthesizing method and application of quinazolinone compound. The quinazolinone compound for preventing and curing plant pathogens is indicated by the general formula (I). Methyl anthranilate, formamide, ethyl bromoacetate, hydrazine hydrate, phenyl isothiocyanate, substitution benzyl halide or 2-chlorine-5 chloromethyl pyridine is used as raw material and subjected to six-step reaction to synthesize the target compound. The quinazolinone compounds A7, A8 and A19 are good in inhibitory activity on rice bacterial leaf blight germs. The quinazolinone compound A19 is good in inhibitory activity on citrus canker germs. The inhibitory activity on wheat scab germs of the quinazolinone compounds A14 and A18 and the inhibitory activity on apple rotting germs of the quinazolinone compound A8 are equal to that of control chemical hymexazol.

Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Disclosed inter alia is the use of quinazolinone derivatives, which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The quinazolinone derivatives are administered with another chemotherapeutic agent selected from alkylating agents, antimetabolites, platinating agents, topoisomerase inhibitors, tubulin agents and signalling inhibitors (e.g., kinase inhibitors). Pharmaceutical compositions comprising one or both types of active agents are also disclosed.

Benzoxazinone and quinazolinone compounds useful in organic light emitting devices (OLEDS) are described.

The invention relates to a method for synthesizing quinazolino indazole derivatives. The method comprises the following steps: using a palladium compound as a catalyst, and producing an intramolecular dehydrogenation coupling reaction of 2-aryl-3-aryl amino quinazolinone derivatives in an oxygen atmosphere in the presence of alkali and a molecular sieve so as to obtain the quinazolino indazole derivatives with diversified structures. The method overcomes the defect that a halogenated compound has to be used as a reaction substrate in the prior art under the synergistic effect of the catalyst, alkali and the molecular sieve, achieves a reaction for efficiently synthesizing the quinazolino indazole derivatives by a one-pot method, has the advantages of high efficiency, environmental friendliness, high yield and purity and the like, expands the application range of the transition metal catalytic dehydrogenation coupling reaction, enriches synthetic methods and paths of the quinazolino indazole derivatives, and has very high theoretical research and application values.

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (Formula (I)) or a pharmaceutically acceptable salt, stereoisomer thereof, wherein G, Y, R, R¹, R^2a, R^2b, R^2c, L, L¹ and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are quinazoline and quinazolinone derivatives and in particular 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds.

A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.